Dear Friends,

As I entered the final days of my tenure as director of VCU Massey Cancer Center, I became more certain than ever of your immense power to bring possibility and hope to life as we strive for a cancer-free world. I have witnessed it, and each year I become more impressed by your generosity, commitment to our mission and faith in the promise of our research. You are the driving force behind our progress, and our fiscal year 2019 discoveries and advancements are evidence of your impact.

Last year, many ongoing projects reached exciting conclusions and entered new phases of research. In 2019, we became the first cancer center to study and show that immune responses to cellular therapies may be predicted, which could allow physicians to help their patients avoid life-threatening complications. We helped usher in a recently FDA-approved, practice-changing breast cancer therapy. We received numerous grants aimed at addressing our country’s vaping epidemic, and we developed the world’s most advanced drug delivery system with the highest tumor-targeting ability. Within these pages, you will find even more stories of success. From major recruitments to collaborative philanthropy, your investment is not only bringing hope to millions of people but also redefining what hope means in the face of a cancer diagnosis. You should take as much pride as we do in our accomplishments, and I hope you are inspired by the opportunity that awaits us over the coming years. I look forward to standing alongside you and cheering Massey on as Dr. Robert Winn takes the helm as the new cancer center director. I have no doubt that Massey will continue to thrive with your support, and we will get closer than ever to a future without cancer.

With gratitude for your partnership and hope for the future,

Gordon D. Ginder, M.D.
Jeanette and Eric Lipman Chair in Oncology
Outgoing director, VCU Massey Cancer Center
Research symposium and donor dinner honor Gordon Ginder for his 22 years of leadership

Hundreds gathered on September 5, 2019, for a research symposium to honor Gordon Ginder, M.D., and his two-plus decades of leadership at VCU Massey Cancer Center. The event featured personal reflections from Ginder’s colleagues and highlights of the scientific achievements made at Massey under his 22-year tenure.

Steven Grossman, M.D., Ph.D., deputy director of Massey and Dianne Nunnally Hoppes Endowed Chair in Cancer Research, shared key accomplishments made in the last two decades. He noted that Massey has grown substantially under Ginder’s leadership, building its scientific base and output fueled by a fourfold increase in extramural, philanthropic and state funding for lifesaving cancer research. He underscored that Ginder successfully led five highly competitive renewals for Massey’s NCI designation and strengthened multidisciplinary care, and that critical, state-of-the-art spaces for cancer research, training and care were developed across the university and health system.

Grossman’s sentiments and admiration are shared by Massey’s philanthropic community, which was evident during the celebratory dinner with donors that followed the symposium. The event honored Ginder’s leadership and provided him an opportunity to thank those who contributed to the Gordon Ginder Research Excellence Fund. The fund will help to advance blood cancer research and continue to support Ginder’s legacy as he shifts his focus to his role as a scientist and hematologist-oncologist at Massey. Thanks to the generosity of Massey’s donor community, the newly established fund has already exceeded $1.15 million.

Ginder addressed Massey’s donor family during dinner and expressed his gratitude for their ongoing support.

Ginder ended both the symposium and dinner with his hallmark grace and humility that has defined his leadership. He thanked his colleagues and Massey’s donor family, crediting them with all that was accomplished during his tenure.

VCU President Michael Rao, Ph.D., his wife, Monica, and Becky and Bill Massey attended the celebrations to honor Ginder’s leadership.

Ginder addressed Massey’s donor family during dinner and expressed his gratitude for their ongoing support.

Massey’s current and former Advisory Board chairs who served throughout Ginder’s tenure attended the dinner. Not pictured is former chair, Pam Royall.
A lasting legacy of hope

Much has changed in the scientific understanding and medical treatment of cancer in the United States in the last two decades due to innovative research. As a result, the number of Americans who are surviving cancer continues to grow. VCU Massey Cancer Center had a hand in many of those lifesaving advancements, and during that same span has evolved into a premier institution for innovative research, patient care and education under the direction of Gordon D. Ginder, M.D.

Leading lifesaving discoveries

In the last 22 years, Massey has developed greater depth and breadth of research in basic, translational, clinical and population science, and interactive research programs. Examples of novel developments that Massey helped to pioneer include pemetrexed (Alimta), a leading chemotherapy for the treatment of lung cancer; multiple innovative radiation therapies, such as accelerated partial breast irradiation, that reduce treatment timeframes and decrease exposure of healthy tissue to radiation; new chemotherapy combinations for the treatment of hematologic malignancies; the use of pre-operative chemotherapy or hormone therapy for breast cancer patients; and a first-ever model that can predict with up to 90% accuracy the amount of nicotine emitted by an electronic cigarette.

The cancer center is also now a prominent leader in disparities research, studying the socioeconomic, cultural and biological forces causing or contributing to disparities in cancer outcomes and developing methods to eliminate those disparities.

Putting patients first

Massey immensely expanded as a multidisciplinary, comprehensive cancer care facility under Ginder’s direction, becoming a referral center for the most complex and rare cancers and expanding treatment options for patients across Virginia and beyond. Among many other landmark care services, the cancer center boasts one of the largest selections of cancer clinical trials in the state; internationally renowned palliative care that is integrated with its cancer care; the largest and most comprehensive bone marrow transplant program in Virginia; a world-class breast health team; in-house, next-generation genome sequencing capabilities for precision cancer treatment; the commonwealth’s first cardio-oncology program; and FDA-approved experimental CAR T-cell therapies.

Inspiring the next generation

Under Ginder’s leadership, Massey was established as a hub of education, successfully competing for training grants; offering training programs and continuing education conferences for oncology health care professionals; providing cancer research training programs for undergraduate, graduate, Ph.D., and pre- and post-doctoral students; and expanding health education to cancer patients and community members through community-engaged research, healthy living programs, resource libraries, seminars, workshops and health fairs.
Building on a strong foundation

As Ginder passes the torch to Massey’s new director, Robert Winn, M.D., the groundwork has already been laid for the future of cancer treatment at Massey in the form of an oncology pavilion, projected to open in 2021, that will consolidate the bulk of the center’s outpatient services on the downtown campus. It will serve as a lasting stamp of the research, training and care facilities that were born across the university and health system during Ginder’s tenure, including the Goodwin Research Laboratory, the first building at VCU dedicated solely to cancer research.

Ginder’s leadership will be remembered as one of service to the community and of fully embodying Massey’s mission to save and improve the lives of those affected by cancer. The Massey sunburst burns brighter today because of his efforts and endures as a beacon of hope for a world without cancer.

---

**UNDER GINDER’S LEADERSHIP (1997-2019)**

<table>
<thead>
<tr>
<th>Massey’s high-impact research publications increased by 429%</th>
<th>429%</th>
</tr>
</thead>
<tbody>
<tr>
<td>The number of Massey’s research projects increased by 57%</td>
<td>57%</td>
</tr>
<tr>
<td>The cancer center increased its NCI peer-reviewed funding by 315%</td>
<td>315%</td>
</tr>
<tr>
<td>Massey developed 264 investigator-initiated clinical research studies</td>
<td>264</td>
</tr>
<tr>
<td>The number of active Massey research members increased 150%</td>
<td>150%</td>
</tr>
<tr>
<td>The Cancer Prevention and Control research program grew from 4 to 56 members</td>
<td>56</td>
</tr>
<tr>
<td>Massey raised nearly $226 million in philanthropic funds</td>
<td>$226M</td>
</tr>
<tr>
<td>In the past 12 years, Massey garnered $82.5 million in State General Funds</td>
<td>$82.5M</td>
</tr>
</tbody>
</table>

---

*Impacting countless lives*

“Ginder’s visionary and dedicated leadership of Massey leaves a lasting legacy that has impacted countless lives within and beyond our community.”

– Marsha Rappley, M.D.
CEO of VCU Health System and Vice President of VCU Health Sciences
Massey physician-researcher Charles Geyer M.D., presented the results of the KATHERINE trial at the San Antonio Breast Cancer Symposium on December 5, 2018. Photo credit: © SABCS/Scott Morgan 2018

Global trial co-led by Massey researcher expected to set new standard of breast cancer care

A phase 3 international trial, known as KATHERINE, found that a drug called trastuzumab emtansine (T-DM1) reduced the risk of cancer recurring by 50% in patients with HER2-positive early-stage breast cancer who had residual disease after receiving neoadjuvant therapy, which is treatment done before surgery to shrink a tumor to make it easier to remove. Massey physician-scientist Charles Geyer, M.D., the Harrigan, Haw and Luck Families Chair in Cancer Research, associate director for clinical research and member of the Developmental Therapeutics research program at Massey, served as global co-chair of the trial.

Data from the trial will be submitted to health authorities around the world, including the U.S. Food and Drug Administration and European Medicines Agency. “I believe these results will be practice-changing,” says Geyer, who is the associate director for clinical research at Massey. “The results should form the foundation of a new standard of care.”

About 15% of all breast cancers are diagnosed as HER2-positive, which refers to cancer that has a large amount of Human Epidermal Growth Factor Receptor 2, a protein that drives tumor growth and makes cancer less responsive to chemotherapy. KATHERINE tested T-DM1 against the current standard treatment and found that it improved the three-year invasive disease-free survival rate by 11.3%. Harry Bear, M.D., Ph.D., Walter E. Lawrence, Jr., Distinguished Professor in Oncology and member of the Developmental Therapeutics research program, was the local principal investigator for the trial at Massey.

Research Highlights

Our scientific achievements would not be possible without visionaries like you. Your investment in a future without cancer enables our researchers to vet new, potentially practice-changing ideas and make groundbreaking discoveries that can be translated into novel therapies. Thanks to you, we continue to be pioneers in shaping the future of cancer research and treatment, bringing hope to patients now and for many generations to come.
Massey scientists develop world’s most advanced drug delivery system with the highest tumor-targeting ability

A team of researchers led by Hu Yang, Ph.D., and Xiang-Yang (Shawn) Wang, Ph.D., members of Massey’s Developmental Therapeutics research program, designed a new drug delivery system to combat a pattern of inadequate blood circulation and low targeting specificity that previous scientific efforts have struggled to overcome. The new platform, called leutosome, is a composite of white blood cells and tumor cells, and, compared to previously researched and reported drug delivery systems, has the highest tumor-targeting ability. Researchers are hopeful that leutosome could lead to improved outcomes and reduced side effects for patients undergoing chemotherapy.

Massey researchers receive nearly $20M grant to predict outcomes of tobacco product regulations

Awarded through a partnership between the National Institutes of Health and the FDA Center for Tobacco Products, the grant launches a five-year project that focuses on predicting the outcomes of government regulations on tobacco products. The goal of the study is to provide the FDA with a suite of tools that they can use to evaluate the effectiveness of potential tobacco product regulations and to aid in protecting human health at a time when e-cigarette use is on the rise. Researchers Thomas Eissenberg, Ph.D., director of the VCU Center for the Study of Tobacco Products, and Alison Breland, Ph.D., are co-PIs of the study and are both members of Massey’s Cancer Prevention and Control research program.
Study shows palliative care associated with shorter hospitalizations and reduced medical costs

Palliative care consultations administered within three days of admission are linked to shorter hospitalizations and significant cost savings for chronically ill adults, according to a large meta-analysis study. The greatest cost reductions attributed to palliative care were seen among cancer patients, who saved an average of more than $4,000 per stay. The study was led by J. Brian Cassel, Ph.D., director of palliative care research and member of the Cancer Prevention and Control Research program at Massey, and Egidio Del Fabbro, M.D., palliative care program director, Palliative Care Endowed Chair and member of Massey’s Developmental Therapeutics research program. Del Fabbro hopes the results of the study encourage other health systems to develop comprehensive palliative care services similar to Massey’s care.

Massey researchers identified protein involved in milk production during pregnancy as a potential target for novel breast cancer therapies

Building upon a decade of work, Charles Clevenger, M.D., Ph.D., Carolyn Wingate Hyde Endowed Chair in Cancer Research, and a team of researchers discovered that the enzyme cyclophilin A (CypA) regulates a genetic pathway responsible for the natural maturation of mammary glands as well as the development of breast cancer cells. By deleting CypA in models, researchers were able to slow or completely halt the growth of breast cancer cells. While no other study to date has examined the role of CypA in the formation of breast cancer, Clevenger, who is a member of Massey’s Cancer Cell Signaling research program, says these findings could be rapidly translated to patients because drugs that inhibit the enzyme are already available.
Innovation funding results in promising implications for new cancer therapies

Massey’s pilot project and multi-investigator programs help launch new ideas and foster collaboration. These programs are in large part fueled by unrestricted donations, which allow Massey to address the greatest needs of the cancer center and prioritize the most promising new research concepts. By providing critical, preliminary investment in novel research ideas, donors like you ensure Massey has the resources needed to advance research projects and position them for additional grant funding. Among the grants Massey researchers receive are R01s, prestigious and highly competitive awards that provide funding for research and development supporting the missions of the National Institutes of Health.

In FY19, three research projects that were initially awarded a total of $149,982 in donor-supported pilot project grants at Massey resulted in approximately $5.28M in total funding from R01s:

Devanand Sarkar, Ph.D., associate director for education and training, Harrison Foundation Distinguished Professor in Cancer Research and member of the Cancer Molecular Genetics research program at Massey, is studying the role of two interacting proteins, AEG-1 and SND1. Previous research conducted by Sarkar has significantly implicated both genes in the development of hepatocellular carcinoma (HCC), the fifth most prevalent cancer overall and the second leading cause of cancer deaths worldwide. Sarkar’s research could result in new cancer therapies for the treatment of HCC.

Scientists Shawn Wang, Ph.D., member of Massey’s Cancer Developmental Therapeutics program, and Xianjun Fang, Ph.D., member of Massey’s Cancer Cell Signaling program, are investigating a new approach to boost the effectiveness of immunotherapies. The researchers are closely examining the relationship between a metabolic process known as fatty acid oxidation (FAO) and its effects on dendritic cells, a key immune system cell type that recognizes threats and recruits other immune cells in response. Models show that genetically disrupting a gene in dendritic cells that affects FAO leads to an improvement in immunotherapy response rates. The researchers are working to understand why this happens and to test their findings in clinical trials.

Hisashi Harada, Ph.D., David Gewirtz, Ph.D., and Joseph Landry, Ph.D., discovered a potential breakthrough in the understanding of tumor dormancy, which could lead to novel cancer therapies. Hisashi Harada, Ph.D., David Gewirtz, Ph.D., and Joseph Landry, Ph.D., member of Massey’s Developmental Therapeutics research program; Hisashi Harada, Ph.D., member of the Cancer Cell Signaling research program; and Joseph Landry, Ph.D., member of the Cancer Molecular Genetics research program, may have uncovered a primary method through which cancer cells exist undetected, evading existing therapies. The trio is investigating the potential for novel therapeutics that target and destroy lung tumor cells in this specific state of tumor dormancy.
Imagine the greatest power to fight cancer already exists within each of us.

That is the promise of immuno-oncology, a new class of cancer treatment that works to harness the body’s own immune system to fight cancer. This promise is why advancing immuno-oncology is an investment and research priority at Massey. By leveraging your donations, the cancer center is already making new discoveries, cultivating immuno-oncology experts and transforming the lives of our patients.

First-of-its-kind research models immune response in cellular immunotherapies

In Massey’s Cellular Immunotherapies and Transplant Program, scientists are pursuing a cross-collaborative effort that could potentially change the way cellular immunotherapies such as stem cell transplantation and CAR T-cell therapies are performed. The grassroots research is primarily funded through pilot project grants supported by unrestricted donations, and it is culminating in a first-of-its-kind body of work that provides a detailed quantitative view of how the immune system responds to cellular therapies.

Lead investigator Amir Toor, M.D., member of the Developmental Therapeutics research program at Massey, and his collaborators recently published three studies that show immune responses are amenable to computation and prediction, which could provide a way for physicians to personalize treatments and improve outcomes from cellular therapies by avoiding potentially life-threatening complications such as graft-versus-host disease in stem cell transplant patients and cytokine release syndrome in CAR T-cell patients.

“Our work represents a major conceptual breakthrough in applying precision medicine to stem cell transplantation and cancer immunotherapy,” says Toor. The researchers will continue to refine their models while working to secure funding to validate their findings and give physicians the ability to measure immune responses in real time and make appropriate adjustments in treatment.
Massey researcher fundraises for cancer research in honor of his wife

As a member of Massey’s Cancer Cell Signaling research program, Santiago Lima, Ph.D., has countless opportunities to see the impact philanthropy has on advancing cancer research. In 2017, his experience went beyond his professional role when his wife, Amanda Dickinson, Ph.D., who also works at VCU as an associate professor of developmental biology, was diagnosed with stage IV melanoma. Dickinson received treatment at Massey, which included cutting-edge immunotherapy, novel drug combinations, surgery and radiation. She is now in remission.

“We believe she was lucky to have been treated at a place like Massey, which is at the forefront of fundamental research and clinical trials that make new treatments possible,” said Lima. “When you hear fundraising campaigns say ‘every dollar makes a difference,’ it is not a slogan, it is a reality. Amanda is living proof of how philanthropy can make a real difference to people.”

Lima now advocates and fundraises for Massey’s cancer research. A former competitive swimmer, he captained Massey’s Swim Across America team and raised thousands of dollars.

Synergy around immuno-oncology investment builds

Seeing the incredible hope that immunotherapy is bringing to Massey patients like Dickinson inspired several longtime supporters of the cancer center to invest in immuno-oncology in FY19. They did more than just give. They collaborated with one another to ensure they were maximizing the impact of their gifts and working to address the cancer center’s most pressing priorities and fund the most promising research.

Thanks to the philanthropic leadership of Darlene and George Emerson, East West Communities Foundation and Judy and Harry Wason, Massey received $6M in immuno-oncology investment last year toward its $20M philanthropic goal. The generosity of these donors also enabled Massey to leverage the Glasgow Trust, which matches endowed research gifts greater than $500,000.

Investment in Massey scientist results in emergence of a new leader in immuno-oncology

Philanthropic support for immuno-oncology at Massey bolsters the cancer center’s ability to recruit and retain the best and brightest scientists like Shawn Wang, Ph.D. Wang joined Massey in 2009 and was awarded a Harrison Scholarship in Cancer Research. Continued investment in Wang’s research and leadership has helped to establish and retain him as a sought-after immuno-oncology expert. He has been awarded numerous prestigious grants, and his work carries practice-changing promise. Thanks to Massey’s donors, Wang continues to drive critical immuno-oncology work at Massey and offer hope to patients everywhere.
After losing her daughter to brain cancer, a mother turned heartbreak into hope

Stoic and sensitive, Anne Worthington Tesiero Beith was a steel magnolia. Friends describe her as a perfectionist and a woman of uncompromising faith and admirable fortitude.

Given these qualities, she, unsurprisingly, excelled in her career at Reynolds Metals Company and served as J. Sargeant Reynolds’ executive secretary before he passed away from a brain tumor. Outside of work, Beith and husband James loved watching their daughter Carol Tesiero grow up to become an independent, studious woman with a passion for the outdoors. Even when Tesiero’s career led her to Smith College in Massachusetts, mother and daughter spoke frequently on the phone. It was during one of these phone calls in 1995 that Beith suddenly noticed a concerning change in her daughter. She and her husband rushed to Tesiero’s side to assess the situation and see how they could help.

Tesiero was suffering from weight loss and severe headaches among other symptoms. Physicians ultimately admitted her to a psychiatric ward for depression. Beith knew, however, that they were missing something, and after working through numerous appointment delays, a CAT scan finally revealed that Tesiero had a brain tumor.

Beith felt it was urgent that her daughter return home to receive treatment at MCV Hospital (as VCU Health and Massey were once known), and knowing that the leadership team at Reynolds Metals Company was familiar with this type of diagnosis, she called upon them for help. The family was soon back in Richmond, courtesy of the company plane.

Unfortunately, Tesiero passed away in September of 1997, and Beith’s husband also passed away that year. For support, Beith leaned on colleagues, friends and the community at Richmond’s First Baptist Church, where she later met and fell in love with Rolfe Beith, whom she married.

Beith found tremendous joy in her golden years, in part through honoring her daughter’s memory by donating to cancer research. As friends explain, Beith wanted to prevent others from experiencing the heartbreak she did. Upon her passing in 2017, Beith left Massey an estate gift, which helped to establish the $1M endowed Carol Tesiero Brain Tumor Research Fund.

Mark Malkin, M.D., who, coincidentally, holds the William G. Reynolds, Jr., Chair in Neuro-oncology, is one of many Massey researchers who will be able to leverage this fund to accelerate and advance neuro-oncology research priorities at Massey. While all of these connections may seem to underscore the immeasurable impact that cancer has on communities, the philanthropic funds donated to honor those we’ve lost are beacons of hope, fueling innovation and research and bringing optimism and promise to patients.

“\nThis is the largest neuro-oncology gift received during my tenure, and Anne and Carol’s story will not be forgotten. Their memory continues through the lives they are helping to improve and save. Their legacy will be defined by hope, and we, and all those impacted by this gift, are grateful for their generosity and belief in our work here at Massey.”

–Mark Malkin, M.D.
Director of Neuro-oncology
Member of Massey’s Developmental Therapeutics research program & William G. Reynolds, Jr., Chair in Neuro-oncology
PHILANTHROPY BY THE NUMBERS
July 1, 2018 – June 30, 2019

$11.1 MILLION
New Gifts & Pledges

13,427 Gifts

$827 Average Gift Amount

10,926 Donors

$4,778,589 Unrestricted Funds Raised

4,019 First-time Donors

MASSEY CLUB
Massey Club members are donors who give $1,000 or more in unrestricted gifts per fiscal year.

$1.5M Unrestricted Annual Giving

538 Donor Families

78% of Unrestricted Funds Come From Massey Club Gifts

Sources of Operating Income to Support Research and Education
$31,846,310
39% State General Fund
23% Philanthropy
21% Grants
17% Institutional

Sources of Philanthropic Funds
$11,116,192
69% Major Gifts and Planned Giving
20% Massey Club and Annual Fund
11% Events and Cause Marketing

Uses of Funding
$31,846,310
36% Faculty Support
25% Clinical Trials Office
15% Research Infrastructure
10% Equipment and Services
7% Basic Science
7% Development

VCU Massey Cancer Center 2018/2019 / 11
Massey Challenge

In April 2019, runners and walkers sporting gold Team Massey shirts dotted the Ukrop’s Monument Avenue 10k course for the 14th year as participants in the Massey Challenge made their miles matter by fundraising for cancer research. The Massey Challenge raised $247,500 thanks to 57 teams and 282 individuals.

Massey on the River

Massey on the River raised a record $139,000 in its 9th year. The fundraiser, hosted by the Massey Alliance, provided a lively platform for celebrating the cumulative power of individual giving and united more than 1,000 attendees for a common cause. The event featured a silent auction, live music, and delicious bites and drinks.

Women & Wellness

The 24th annual Women & Wellness Breakfast and Luncheon featured keynote speaker Samantha Harris, an award-winning TV host, author and breast cancer survivor. The fundraiser, along with supporting events, raised $225,000 for women’s cancer research at Massey.

Richmond Brunch Weekend

The fourth annual Richmond Brunch Weekend boasted a record 54 participating restaurants, all of which donated at least 15% of their brunch proceeds to Massey. Coordinated by the Massey Alliance, the weekend-long give-back event raised $34,500.
Community partners reach philanthropic milestones

We are continuously uplifted and inspired by the incredible support the community provides through give-back nights, fundraisers, sponsorships and event participation. In FY19, 42 community partner events raised more than $440,000, and we were thrilled to welcome new sponsors, Massey Challenge teams and others to join us in our efforts to eradicate cancer.

First Citizens Bank teams up with Massey to champion communitywide fundraising program

First Citizens Bank became the inaugural presenting sponsor of Team Massey, a grassroots fundraising initiative. Inspired by the commitment of Massey’s advocates to support cancer research, First Citizens Bank championed Team Massey’s cause and message throughout the state. With company values rooted in making a difference in the communities they serve, First Citizens Bank has a 121-year history of giving back, and supporting those touched by cancer has long been a priority.

Heartbreak and hope inspire Long & Foster to join the Massey Challenge

A first-time Massey Challenge team, Long & Foster raised nearly $28,000 for cancer research at Massey, exceeding their original goal by $12,000. Many of the participating Long & Foster employees were motivated to participate by their personal experiences with cancer, and they welcomed the opportunity to support future lifesaving advances. Their team, Agents of Hope, is already looking forward to participating again in 2020.

Renowned jewelry designer supports women’s cancer research

Fink’s Jewelers hosted renowned jewelry designer David Yurman in their Short Pump store in April, with a portion of sales benefiting the Women & Wellness Fund. The in-store shopping event was a success, and Fink’s and David Yurman gave Massey a significant donation to support women’s cancer research.

Swim Across America provides new fundraising opportunity

On the morning of Saturday, October 2018, about 50 people snapped swim caps over their heads, adjusted their goggles and waded into the currents of the upper James River. While all of the participants in the inaugural swim benefit tackled different distances that day, they still shared a common goal: make waves to fight cancer. Participants used their swim as a platform to raise money for Massey, and their collective impact totaled more than $30,000.
Forging ahead with the best and brightest minds

Many of our physician-scientists are international leaders in their fields. We have more than 100 ongoing clinical trials and research studies, and 40% of our trials are investigator initiated, which means they evolved from studies started by Massey’s own researchers and were initially funded, in part, by philanthropy. Your donations provide the critical resources needed to retain and recruit the most innovative minds to lead and shape cancer research at Massey, and we thank you for your investment in our workforce. In FY19, philanthropic funds enabled us to welcome new recruits to join our team of distinguished scholars, scientists and accomplished clinicians, and we are thrilled to welcome new research members in each of our core programs.

New Recruits

<table>
<thead>
<tr>
<th>New Recruits</th>
<th>Suyun Huang, M.D., Ph.D., Human and Molecular Genetics</th>
<th>Alexander Neuwelt, M.D., Internal Medicine and Hunter Holmes McGuire VA Medical Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azeddine Atfi, Ph.D., Pathology</td>
<td>Howard Li, M.D., Internal Medicine and Hunter Holmes McGuire VA Medical Center</td>
<td>Sâlid Sebti, Ph.D., Pharmacology and Toxicology</td>
</tr>
<tr>
<td>Tytus Bernas, M.Sc., Ph.D., Anatomy and Neurobiology</td>
<td>Jiong Li, Ph.D., Medicinal Chemistry</td>
<td>Stephanie Sullivan, M.D., Obstetrics and Gynecology</td>
</tr>
<tr>
<td>Wook-Jin (Eddie) Chae, Ph.D., Microbiology and Immunology</td>
<td></td>
<td>Guizhi (Julian) Zhu, Ph.D., Pharmaceutics</td>
</tr>
<tr>
<td>Ronald Gartenhaus, M.D., Internal Medicine and Hunter Holmes McGuire VA Medical Center</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

New Research Program Members

<table>
<thead>
<tr>
<th>New Research Program Members</th>
<th>James Lister, Ph.D.</th>
<th>Binu John, M.D., M.P.H., FACG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Cell Signaling</td>
<td>Cancer Prevention and Control</td>
<td>Brian Kaplan, M.D.</td>
</tr>
<tr>
<td>Azeddine Atfi, Ph.D.</td>
<td>Elizabeth Do, Ph.D., M.P.H.</td>
<td>Howard Li, M.D.</td>
</tr>
<tr>
<td>Wook-Jin (Eddie) Chae, Ph.D.</td>
<td>Jennifer Jordan, Ph.D., M.S.</td>
<td>Alexander Neuwelt, M.D.</td>
</tr>
<tr>
<td>Rebecca Martin, Ph.D.</td>
<td>Sun Jung (Sunny) Kim, Ph.D., M.S., M.A.</td>
<td>Gary Simmons, D.O.</td>
</tr>
<tr>
<td>Jason Newton, Ph.D.</td>
<td>Alexander Lucas, Ph.D.</td>
<td>Stephanie Sullivan, M.D.</td>
</tr>
<tr>
<td>Sandeep Singh, Ph.D.</td>
<td>Gretchen Neigh, Ph.D.</td>
<td>Guizhi (Julian) Zhu, Ph.D.</td>
</tr>
</tbody>
</table>

| Developmental Therapeutics | Hamid Akbarali, Ph.D. | Adam Sima, Ph.D., non-aligned member |
A hopeful horizon

Working on the frontier of hope means that our researchers are always heading toward a new horizon that will bring optimism and promise to those affected by cancer. As we look ahead, we can already see that Massey has some incredible milestones and advancements on the horizon, and we look forward to continuing to partner with you as we reach them and inch ever closer to a future without cancer.

In December 2019, Robert Winn, M.D., took the reins as VCU Massey Cancer Center’s new director after Gordon Ginder, M.D., stepped down from 22 years of leadership. We look forward to learning more about his vision and building upon Ginder’s efforts to elevate Massey’s designation by the National Cancer Institute to Comprehensive Cancer Center.

The 2020 Women & Wellness Breakfast and Luncheon marks the 25th anniversary of the event. A cornerstone of Massey’s philanthropic community, the event has helped raise more than $5M for women’s cancer research.

Massey continues to collaborate with other experts within VCU to explore drug discovery and development at Massey. The program aims to enable Massey to develop and test novel therapeutic agents so they can be translated into new, more effective cancer treatments for all.

Construction of Massey’s new outpatient pavilion is steadily progressing. The new facility, located on Leigh Street at 10th and 11th Streets, will double the number of infusion chairs, house state-of-the-art treatment technologies and offer more convenient access to patients with on-site parking and the consolidation of cancer clinics and imaging in the same building.
Endowed Chairs, Professors and Scholars
as of June 2019

Established through the generosity of donors, these gifts provide a perpetual source of income and are a critical tool in recruitment and retention of the best and brightest minds, building Massey’s reputation as a center for innovation. Endowed chairs, professorships and scholars also recognize the distinction of outstanding faculty while providing invaluable support for Massey’s most distinguished researchers. Massey is grateful for the philanthropic funds given to support the following:

**Chairs**

<table>
<thead>
<tr>
<th>Florence and Hyman Meyers Chair in Radiation Oncology</th>
<th>Harrigan, Haw, Luck Families Chair in Cancer Research</th>
<th>William G. Reynolds, Jr., Chair in Neuro-Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas W. Arthur, M.D.</td>
<td>Charles E. Geyer, Jr., M.D.</td>
<td>Mark G. Malkin, M.D.</td>
</tr>
<tr>
<td>Carolyn Wingate Hyde Endowed Chair in Cancer Research</td>
<td>Jeanette and Eric Lipman Chair in Oncology</td>
<td>Linda Grandis Blatt Endowed Chair in Cancer Research</td>
</tr>
<tr>
<td>Charles Clevenger, M.D., Ph.D.</td>
<td>Gordon D. Ginder, M.D.</td>
<td>S. Patrick Nana-Sinkam, M.D.</td>
</tr>
<tr>
<td>Palliative Care Endowed Chair</td>
<td>Shirley Carter Olsson and Sture Gordon Olsson Chair in Cancer Research</td>
<td>Lacy Family Chair in Cancer Research</td>
</tr>
<tr>
<td>Egidio Del Fabbro, M.D.</td>
<td>Steven Grant, M.D.</td>
<td>Said Sebti, Ph.D.</td>
</tr>
<tr>
<td>Universal Corporation Chair in Cancer Cell Signaling</td>
<td>Dianne Nunnally Hoppes Endowed Chair in Cancer Research</td>
<td>Theresa A. Thomas Memorial Foundation Chair in Cancer Prevention and Control</td>
</tr>
<tr>
<td>Paul Dent, Ph.D.</td>
<td>Steven R. Grossman, M.D., Ph.D.</td>
<td>Vanessa B. Sheppard, Ph.D.</td>
</tr>
<tr>
<td>Thelma Newmeyer Corman Endowed Chair in Oncology Research</td>
<td>Paul M. Corman, M.D., Chair in Cancer Research</td>
<td>Mann T. and Sara D. Lowry Chair in Oncology</td>
</tr>
<tr>
<td>Paul B. Fisher, M.Ph., Ph.D.</td>
<td>Suyun Huang, M.D., Ph.D.</td>
<td>Sarah Spiegel, Ph.D.</td>
</tr>
<tr>
<td>Gordon D. Ginder, M.D., Chair in Cancer Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bernard Fuemmeler, Ph.D., M.P.H.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Professorships**

<table>
<thead>
<tr>
<th>Martha Anne Hatcher Distinguished Professor in Oncology</th>
<th>Irene Shaw Grigg Distinguished Professor in Genetics Research</th>
<th>Jolene J. Windle, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew C. Lamer, M.D., Ph.D.</td>
<td>Jolene J. Windle, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Harrison Foundation Distinguished Professor in Cancer Research</td>
<td>Walter E. Lawrence, Jr., Distinguished Professor in Oncology</td>
<td>Harry D. Bear, M.D., Ph.D.</td>
</tr>
<tr>
<td>Devanand Sarkar, MBBS, Ph.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Scholars**

<table>
<thead>
<tr>
<th>Harrison Scholars</th>
<th>Victor Yazbeck, M.D.</th>
<th>Massey Alliance Scholar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larisa Litovchick, M.D., Ph.D.</td>
<td></td>
<td>Sarah Gordon, D.O.</td>
</tr>
<tr>
<td>Andrew Poklepovic, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Pending Appointment**

<table>
<thead>
<tr>
<th>The Natalie N. and John R. Congdon, Sr., Endowed Chair</th>
<th>Harry and Judy Wason Distinguished Professor</th>
<th>Dianne Harris Wright Professor and Dianne Harris Wright Professor for OB-GYN Oncology Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Faber, Ph.D.</td>
<td>Xiang-Yang (Shawn) Wang, Ph.D.</td>
<td>Leslie Randall, M.D.</td>
</tr>
</tbody>
</table>

**Active Recruitment**

<table>
<thead>
<tr>
<th>Children’s Hospital Foundation Endowed Chair in Pediatric Cancer Research</th>
<th>Mary Anderson Harrison Distinguished Professorship in Cancer Research</th>
<th>Veronica Donovan Sweeney Professorship for the Chief of Breast Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Massey Cancer Center Chair in Cancer Cell Signaling</td>
<td>Massey Club Professorship</td>
<td>Susan White Holsworth Palliative Care Scholar</td>
</tr>
<tr>
<td>Judith Talley Secor Chair</td>
<td>RGC Professorship for Cancer Research</td>
<td></td>
</tr>
</tbody>
</table>
Massey Alliance Board

Massey Alliance Board Officers
Meg Irvin, President
Sara Woznicki, President Elect
Abbey Withrow, Immediate Past President
Margot Adams McDonald, Secretary

Massey Alliance Board Members
O’Conor Ashby
Peter Bonelli
Andrea Buono
Katie Butz
Tell Carlson
Bryce Carson
Katie Clark
Lara Falcone
Ashton Farrar
Leanne Ferry
Ben Ferry
Michael Hofmeister
Anny Irons
Sarah Jenks
Lisa Kurczewski
Gary LeClair, Jr.
Philip Matthews
William McGoogan
Clint Nichols
Stuart Paykel
Christopher Reina
Nicholas Shedd
Tyler Sorenson
Megan Sullivan
Steven Valdez
Rebecca Vokes
Elliott Warren
Thomas Warthen
Emily Younts
Keith Zirkle

Advisory Board

Officers of the Board
L. Michael Gracik, Jr., Chair
Anne Whittemore, Vice Chair
George P. Emerson, Jr., Immediate Past Chair

Board Members
Ralph H.B. Anderson, DDS., M.S.
Shelly E. Arthur
Ann H. Austin
Catherine M. Bayliss
Susan M. Benson
Mary D. Billey
Roger L. Boevé
Jean Ann Bolling
Joanna A. Brennan
J. Alfred Broaddus
Judy S. Brown
Charles L. Cabell
Jill Thalhimer Campbell
Judith T. Clough
David S. Cohn
John R. Congdon, Jr.
Joelle Cosby
Sarah Cossé
Paul W. Croston
Wesley I. Crowder
Melvin L. Davis, Jr.
Erika T. Davis
Preston Dillard
James Donaldson
Bromby Luck Earle*
Kathryn Funk
Corinne Garland
Cheryl Goddard
Bea González
Bill Hamill
Theodore S. Hanson
Terrell Luck Harrigan
Elizabeth S. Hart
Karen D. Higgins
Kenneth Hitchens
Olin V. Hyde*
Tracey Jameson
Joseph R. Jenkins
Mark Johnson
Linwood A. Lacy, Jr.
Jarold D. Langley
Betty Sue Grandis LePage
Gail Letts
John B. Lewis
James Ludwig
David A. Lyons
Rebecca C. Massey
A. Travis Massey
Patricia Merrill
James Scott Merritt III
Henry R. Miller, IV
David Mills
James T. Napier
Julian T. Ottley
Kathryn H. Pearson
Catherine S. Plotkin
Martha Orr Proutt
Pamela Kiecker Royall
Helen Ryan
Frances Santarella
Lisa Sharpe
Lisa Sims
Susan Sisisky
Raymond M. Slabaugh III
Vickie M. Snead
Judith Forehand Starkey
Levar Stoney
Elizabeth H. Thornton
Robert G. Whitten
Amy McDaniel Williams

Emeritus Board Members
William G. Broaddus, Esquire
Charles F. Crone
James E. Farnham, Esquire
Alice T. Goodwin
Bertha C. Rolfe
E. Morgan Massey
Adrienne L. Maxwell
Matthew G. Thompson
Judith H. Turbeville

* Bromby and Olin passed away in 2018 and 2019, respectively. We thank them for their generous board service and heartfelt commitment to Massey’s mission.
Support Massey
To make a contribution or inquire about ways to give, call the Office of Development and External Relations at 804.828.1450.

Visit masseycancercenter.org/support to make a gift online.

Make an Appointment
Call 804.828.5116 or 1.877.4MASSEY.

Volunteer
To get involved with special events and fundraisers, call 804.628.1663.
To volunteer to serve patients, call 804.828.0922.

www.masseycancercenter.org